TScan Therapeutics (TCRX) Other Gross PP&E Adjustments (2020 - 2025)
Historic Other Gross PP&E Adjustments for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to -$59.9 million.
- TScan Therapeutics' Other Gross PP&E Adjustments rose 107.86% to -$59.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$59.9 million, marking a year-over-year increase of 107.86%. This contributed to the annual value of -$39.9 million for FY2024, which is 566.48% up from last year.
- As of Q3 2025, TScan Therapeutics' Other Gross PP&E Adjustments stood at -$59.9 million, which was up 107.86% from -$62.6 million recorded in Q2 2025.
- In the past 5 years, TScan Therapeutics' Other Gross PP&E Adjustments ranged from a high of $10.4 million in Q4 2021 and a low of -$63.5 million during Q1 2025
- Over the past 5 years, TScan Therapeutics' median Other Gross PP&E Adjustments value was -$50.4 million (recorded in 2023), while the average stood at -$38.3 million.
- Per our database at Business Quant, TScan Therapeutics' Other Gross PP&E Adjustments skyrocketed by 285681.82% in 2021 and then tumbled by 118009.95% in 2023.
- Quarter analysis of 5 years shows TScan Therapeutics' Other Gross PP&E Adjustments stood at $10.4 million in 2021, then plummeted by 479.41% to -$39.5 million in 2022, then dropped by 7.07% to -$42.3 million in 2023, then grew by 5.66% to -$39.9 million in 2024, then plummeted by 50.15% to -$59.9 million in 2025.
- Its last three reported values are -$59.9 million in Q3 2025, -$62.6 million for Q2 2025, and -$63.5 million during Q1 2025.